In one paragraphReview in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
27 authors.
Burak KundakciCentre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, England, UK.ORCID 0000-0002-3507-1111 Megan R W BarberDivision of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Ann E ClarkeDivision of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-3112-9646 Sindhu R JohnsonInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0003-0591-2976 Anselm MakDivision of Rheumatology & Allergy, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.ORCID 0000-0002-4688-7829 Hermine I BrunnerDepartment of Pediatrics and Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
Murat InancDivision of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Fatih, Turkey.ORCID 0000-0002-6376-5583 Rosalind Ramsey-GoldmanDepartment of Medicine/Division of Rheumatology, Feinberg School of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Guillermo Ruiz-IrastorzaBiobizkaia Health Research Institute, UPV/EHU - University of the Basque Country, Bizkaia, The Basque Country, Spain.ORCID 0000-0001-7788-1043 Ellen M GinzlerRheumatology Division, Department of Medicine, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA.ORCID 0000-0002-7306-7375 John G HanlyDivision of Rheumatology, Department of Medicine, Queen Elizabeth II Health Sciences Center and Nova Scotia Health; Dalhousie University, Halifax, Nova Scotia, Canada.ORCID 0000-0003-1029-9483 Alexandra LeggeDivision of Rheumatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.ORCID 0000-0003-0373-4985 Cynthia AranowInstitute of Molecular Medicine, Center for Autoimmune, Musculoskeletal and Hematopoietic Disease, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA.ORCID 0000-0001-9299-0053 Laurent ArnaudDepartment of Rheumatology, National Reference Center for Autoimmune Diseases (RESO), INSERM UMR-S 1109, Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France.ORCID 0000-0002-8077-8394 Nathalie Costedoat-ChalumeauService de Médecine Interne, Centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares d'Ile-de-France, de l'Est et de l'Ouest, Hôpital Cochin, AP-HP, Paris, France.ORCID 0000-0002-1555-9021 Dafna D GladmanDivision of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals, Toronto, Ontario, Canada.ORCID 0000-0002-9074-0592 Søren JacobsenCopenhagen Lupus and Vasculitis Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Île-de-France, Denmark.ORCID 0000-0002-5654-4993 Michelle A PetriDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1441-5373 Clovis A SilvaPediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Evelyne VinetDivisions of Rheumatology & Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0001-7727-5879 Alexandre E VoskuylDepartment of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0002-9699-1827 SDI Revision Leadership Team
SDI Revision Literature Review Groups
SDI Revision Delphi Panel
SDI Revision Item Reduction Committee
SDI Revision Clinical Domain Groups
Ian N BruceCentre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, England, UK i.bruce@qub.ac.uk.ORCID 0000-0003-3047-500X Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
objectiveA data-driven and expert/patient consensus-based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results for a revised SDI.
methodsItem generation included a literature review by literature review groups and a Delphi exercise of international systemic lupus erythematosus experts and patients. Item reduction involved Delphi rounds in which items with a median appropriateness score of ≤ 4 of 9 were excluded. A 14-member item reduction committee assessed remaining items and removed those that did not reflect the damage construct, were rare, or were not feasible to assess. The clinical domain groups then refined the remaining items and their definitions.
resultsThe Delphi panel included 146 individuals from 35 countries. The Delphi exercise nominated 2256 items, and the literature review identified 117 items. After removing redundancies, 226 candidate items remained. Subsequent Delphi rounds, followed by review by the item reduction committee and clinical domain groups, resulted in 39 items across 13 domains. Eleven items from the original SDI, including proteinuria and cranial neuropathy, were removed and several new items were proposed, including growth failure/reduced final height and adrenal insufficiency. Severity-based subitems are proposed for 17 items (43.6%).
conclusionThis data-driven and expert/patient consensus-based process has proposed 39 candidate items, some with subitems, and definitions for a revised SDI. Weighting of items and subitems is underway to develop a clinical scoring system.
Indexed as
Lupus Erythematosus, SystemicSeverity of Illness IndexConsensus Statements as TopicDelphi TechniqueHumansGlucocorticoidsLupus Erythematosus, SystemicMortality
Identifiers
PMID42586611
PMCPMC13475098
What OpenQuestion holds
Textmetadata
Read underepoch 390